Table 5.
Treatment scenarios
| No. | Scenario | Purpose |
|---|---|---|
| 1 | Varying treatment cost | To determine a treatment cost that is economically justified under base-case assumptions |
| 2 | Treatment effect on psychiatric medication use | To determine whether changing NPI symptoms that are linked to psychiatric medication use can play any role in better capturing treatment effects |
| 3 | Including cost of AEs | To explore how much the new treatment can impact the AE costs associated with psychiatric medication use |
| 4 | Varying time horizon | To compare the cost-effectiveness of the new treatment in the short term vs. long term (2, 5, 10, 20 years) |
| 5 | Treatment discontinuationa | To determine how cost-effective the new treatment would be if it was discontinued after 1, 2, or 5 years |
| 6 | Varying disease severity | To determine how patients with different AD disease severity benefit from the new treatment |
| 7 | Redistributing treatment effects among NPI subscales | To determine the treatment effects on which combination of NPI subscales results in a greater benefit |
| 8 | Increasing treatment effects on NPI subscales and ADAS-Cog | To determine the total treatment effects required to make the new treatment cost-effective |
| 9 | Changing longitudinal effect of NPI subscales on mortality | To explore the effect of directly linking the change in NPI symptom scores to mortality hazard |
| 10 | Linking NPI subscales to risk of institutional placement | To explore the effect of new treatment in reducing the risk of institutionalization |
| 11 | Combined effects of scenarios 3, 4, 6, 8, and 9 | To explore the maximum effect achievable |
ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; AD, Alzheimer disease; AE, adverse event; NPI, Neuropsychiatric Inventory.
a
Treatment discontinuation resulted in a return to clinical values as if the patient had never been treated.